One Day MD | Evidence-Based Wellness

By Dr Frank Yap, MD | Medically reviewed by the One Day MD Editorial Team | Last updated: August 2026 | Original publication: March 2023 Quick Answer A 2024–2025 meta-analysis of 50 RCTs (4,150 patients) confirms berberine modestly but reliably lowers fasting glucose, HbA1c, LDL cholesterol and inflammatory markers in type 2 diabetes and metabolic syndrome — solid, Tier 1a evidence. It is not "nature's Ozempic." Semaglutide produces roughly 10–15%+ body-weight loss in trials; berberine averages only about 2–4 lb a month. The mechanisms and effect sizes aren't comparable. Typical dosing is 500 mg, 2–3x daily with meals (1,000–1,500 mg/day). Bioavailability — not the milligram number on the label — is the biggest real difference between brands. New in 2026: A draft EU/UK scientific opinion (EFSA/COT, March 2026) flagged in-vitro genotoxicity signals, confirmed the CYP3A4 drug-interaction risk, and stated that regulators cannot yet establish a formal "...

Preventive Medicine & Longevity > Cancer Prevention Medically reviewed and updated by the OneDayMD Editorial Team | Originally published: January 2026 | Substantially revised and expanded: August 2026 Source: American Cancer Society, Cancer Facts & Figures 2026 ; Siegel et al., Cancer Statistics, 2026 , CA Cancer J Clin. What actually reduces cancer risk — organ by organ — based on human evidence, not headlines or supplements. This guide is a core cluster article within OneDayMD's Preventive Medicine & Longevity hub . It focuses on risk reduction , not guarantees, and prioritizes interventions supported by epidemiology and clinical data over mechanistic or anecdotal claims. Quick Answer The strongest, most consistent evidence for reducing cancer risk comes from a short list of factors that reappear across nearly every organ system: not smoking, limiting alcohol, maintaining a healthy weight, staying physically active, and keeping up with va...